The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Updated analysis of phase II trial of irinotecan/s-1/cetuximab (IRIS/Cet) as second-line treatment in patients with KRAS exon2 wild type metastatic colorectal cancer (mCRC): HGCSG0902—Comparison of administration interval in cetuximab treatment.
 
Tomohiro Kondo
No Relationships to Disclose
 
Satoshi Yuki
Honoraria - Bristol-Myers Squibb; Taiho Pharmaceutical; Taiho Pharmaceutical; Yakult Honsha
 
Yasuyuki Kawamoto
No Relationships to Disclose
 
Yasushi Tsuji
No Relationships to Disclose
 
Ayumu Hosokawa
No Relationships to Disclose
 
Michio Nakamura
Honoraria - Yakult Honsha
Research Funding - Taiho Pharmaceutical (Inst)
 
Osamu Muto
No Relationships to Disclose
 
Takashi Kato
No Relationships to Disclose
 
Ichiro Iwanaga
No Relationships to Disclose
 
Atsushi Sato
No Relationships to Disclose
 
Kazunori Eto
No Relationships to Disclose
 
Kouichi Furukawa
No Relationships to Disclose
 
Hideyuki Hayashi
No Relationships to Disclose
 
Miki Tateyama
No Relationships to Disclose
 
Yasuo Takahashi
No Relationships to Disclose
 
Susumu Sogabe
No Relationships to Disclose
 
Takuya Honda
No Relationships to Disclose
 
Yuh Sakata
Consulting or Advisory Role - Taiho Pharmaceutical; Taiho Pharmaceutical; Yakult Pharmaceutical
 
Yoshito Komatsu
Honoraria - Daiichi Sankyo; Merck Serono; Taiho Pharmaceutical; Yakult Honsha
Research Funding - Daiichi Sankyo; Merck Serono; Taiho Pharmaceutical; Yakult Pharmaceutical